

PATIENT NAME: _____

TREATMENT START DATE: _____

TREATMENT REGIMEN: _____

Activity	Baseline	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18
Date																			
CLINICAL MONITORING																			
Sputum smear and culture ¹	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Imaging ² (CXR, CT, other)	☐						☐						☐						
Weight ³ and baseline BMI	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Symptom review ⁴	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Clinician evaluation	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
DST ⁵	☐																		
LAB MONITORING FOR TOXICITY / CO-MORBIDITIES																			
CBC ⁶	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Creatinine ⁷	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
LFTs ⁸	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
K, Ca, Mg, bicarbonate ⁹	☐	☐	☐	☐	☐	☐	☐	☐	☐										
Lipase/amylase ¹⁰	☐																		
Drug level ¹¹		☐																	
TSH ¹²	☐		☐				☐						☐			☐			☐
HIV (± viral hep serology) ¹³	☐																		
Pregnancy	☐																		
MONITORING PROCEDURES																			
Audiogram & vestibular exam ¹⁴	☐	☐	☐	☐	☐	☐	☐	☐	☐										
Vision exam ¹⁵	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Peripheral neuropathy ¹⁶	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Arthralgias ¹⁷	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
Depression ¹⁸	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐	☐
ECG ¹⁹	☐	☐	☐	☐	☐	☐	☐	☐	☐										

*Important: Monitoring recommendations may change if treatment regimen or patient status changes. A box indicates monitoring activity is recommended. Check box when activity is completed. Updated 6/22/2022

1. Collect 3 sputum specimens for AFB smear and culture at baseline and at least 1 sample every 1-2 wks, then 1-2 specimens monthly until culture conversion, then at least 1 sample monthly until end of treatment.

2. Obtain baseline imaging and monitor every 3 mos during treatment (every 6 mos in year 2 when treating beyond 1 year). Consider obtaining end of treatment imaging to serve as new baseline going forward.

3. Monitor weight monthly and adjust medications as needed.

4. Monitor for symptoms monthly documenting when symptoms resolve.

5. Obtain 1st and 2nd-line DST results at baseline. Repeat if patient on RIPE and remains culture positive prior to MDR-TB treatment start, and again if patient fails to convert culture after 3 mos on treatment.

6. Obtain CBC with diff every 1-2 wks for first 6-8 wks, then monthly thereafter while taking LZD.

7. Obtain serum creatinine at baseline and monthly while taking BPd, or an injectable agent.

8. LFTs (ALT, AST, T.bil, Alk phos) at baseline then monthly while on BDQ, Pa, PZA, ETA or PAS; consider checking at week 2 of treatment in patients with increased risk for hepatotoxicity.

9. K, Ca, Mg, and bicarbonate at baseline and monthly while taking BDQ or an injectable agent.

10. Consider checking lipase (±/- amylase) if underlying concerns for pancreatitis or if symptoms develop.

11. Therapeutic drug monitoring (TDM) should be obtained for patients receiving CS or LZD after 1-2 weeks on target dose. TDM may be obtained for other drugs as clinically indicated.

12. Obtain TSH at baseline and every 3 mos when initiating ETA or PAS. Consider more frequent monitoring if symptoms or abnormalities. Consider baseline TSH if concerns for prolonged QT interval on baseline ECG.

13. Obtain baseline HIV test for all. Consider viral hep serology testing for those with risk factor for Hep B or C.

14. Perform audiogram and vestibular exam at baseline then monthly while taking an injectable agent.

15. Perform visual acuity + color discrimination exams at baseline and monthly while taking EMB or LZD.

16. Monitor for peripheral neuropathy at baseline and monthly when taking LZD and as clinically indicated for patients on fluoroquinolones (MFX/LFX).

17. Monitor for arthralgias at baseline and monthly while taking PZA or fluoroquinolone (MFX/LFX).

18. Monitor for depression at baseline and monthly while taking CS.

19. Obtain ECG and check QTcF at baseline and at least 2, 12, and 24 weeks when taking BDQ. Consider checking monthly if taking additional QT prolonging agents (e.g., MFX, CFZ, other).